Clinical AI company Sensyne Health has signed an agreement with Oxford University to conduct a multi-omics drug discovery research project in asthma.
The three-year project will focus on identifying novel drug targets for patients with severe forms of asthma that do not respond to the current standard of care and where pre-existing treatments such as corticosteroids and biologics are less effective.
Sensyne will apply its machine learning expertise and analytical tools to analyse complex genetic, phenotypic, and electronic patient record data sets for the Oxford University ‘MultiOmics Project Study Genomics Asthma Project’ (“MORSE”). The combination of three data sets will provide a platform for the identification of novel drug targets for the treatment of severe forms of asthma.
Sensyne Health will own any IP from any novel drug target identified through the research and will give a royalty payment back to Oxford University and the Oxford University Hospitals NHS Foundation Trust in line with the Strategic Research Agreements entered into between the parties and Sensyne in 2018.
Throughout the research, the parties will look to undertake whole genome sequencing (WGS) of highly-phenotyped adult patients with severe forms of asthma from the Oxford Severe Asthma cohort. Data will be compared with controls to identify novel variations associated with specific highly defined asthma phenotypes.
More so, samples from patients who have undergone WGS will be analysed using detailed transcriptomics. Finally, the partners will develop a bioinformatic analysis pipeline which can integrate these datasets and provide proof of concept in identifying novel information on pathways and phenotypes.
According to the World Health Organisation, asthma affected over 250 million people in 2019 and was responsible for 461,000 deaths.
Dr Timothy Hinks, senior research fellow at the University of Oxford and Honorary NHS Consultant at the John Radcliffe Hospital, said: “As a clinician caring for people with severe and difficult-to-treat asthma I’m hugely excited about this collaboration. Asthma affects 1 in 12 adults in UK and severe forms of asthma has a major impact on people’s lives with time off school and work, and hospital admissions. We still don’t understand the causes of asthma, because in the past the scientific tools just didn’t exist. Now we’re at a point in history that we can use tiny samples from the airways of volunteers and study individual cells in incredible detail measuring how each gene is controlled, one cell at a time. As a scientist I’m optimistic this is going to bring about really significant new insights into the mechanisms that drive asthma, so we can develop some new treatments for this, the world’s most common long-term lung condition.
“This project is only made possible through a ground-breaking partnership between the University of Oxford, Sensyne Health and Oxford University Hospitals NHS Foundation Trust, sharing our resources and expertise to tackle a common problem.”
Chas Bountra pro-vice chancellor for Innovation and professor of Translational Medicine at the University of Oxford, said: “Partnering with industry is crucial for accelerating the life-changing, world-class research we do here at the University of Oxford. We are pleased to be working with Sensyne Health on this important project which will enable our scientists to look for breakthrough drug discoveries to combat respiratory disease.”